Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Double-blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Safety and Pharmacokinetics Trial of Inhaled Niclosamide in Healthy Adult Subjects

Next Previous
Trial Profile

Phase 1, Double-blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Safety and Pharmacokinetics Trial of Inhaled Niclosamide in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niclosamide (Primary)
  • Indications COVID-19 respiratory infection
  • Focus Adverse reactions
  • Sponsors TFF Pharmaceuticals

Most Recent Events

  • 19 Apr 2022 Results published in TFF Pharmaceuticals Media Release
  • 01 Feb 2022 Status changed from active, no longer recruiting to completed.
  • 27 Jan 2022 According a TFF Pharmaceuticals media release, the safety management committee has recommended the 6.0 mg BID (12 mg total daily dose) as safe for progression into Phase 2 testing.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top